Erratum to: Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials

Published Erratum

. 2017 Jul;34(7):1772.

doi: 10.1007/s12325-017-0563-2.

Affiliations

¹ TCR Medical Corporation, San Diego, CA, USA. sadsit@therapeuticsinc.com.
² Dermos, Guatemala City, Guatemala.
³ UCLA School of Medicine, Los Angeles, CA, USA.
⁴ Halitus, Buenos Aires, Argentina.
⁵ Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico.
⁶ Riesgo de Fractura S.A., Bogota, Colombia.
⁷ Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁸ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
⁹ Novartis Pharma AG, Basel, Switzerland.

Published Erratum

Sandra Adsit et al. Adv Ther. 2017 Jul.

. 2017 Jul;34(7):1772.

doi: 10.1007/s12325-017-0563-2.

¹ TCR Medical Corporation, San Diego, CA, USA. sadsit@therapeuticsinc.com.
² Dermos, Guatemala City, Guatemala.
³ UCLA School of Medicine, Los Angeles, CA, USA.
⁴ Halitus, Buenos Aires, Argentina.
⁵ Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico City, Mexico.
⁶ Riesgo de Fractura S.A., Bogota, Colombia.
⁷ Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁸ Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
⁹ Novartis Pharma AG, Basel, Switzerland.

No abstract available

Erratum for

Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Adsit S, Zaldivar ER, Sofen H, Dei-Cas I, Maldonado-García C, Peñaranda EO, Puig L, Meng X, Fox T, Guana A. Adsit S, et al. Adv Ther. 2017 Jun;34(6):1327-1339. doi: 10.1007/s12325-017-0521-z. Epub 2017 Apr 10. Adv Ther. 2017. PMID: 28397079 Free PMC article. Clinical Trial.